New eye drops aim to restore natural moisture in dry eyes
NCT ID NCT06544694
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new eye drop called AR-15512 can improve the health of the eye surface in people with dry eye disease. 80 participants received either the new drops or artificial tears. The main goal was to see if the drops increased the number of goblet cells, which help keep the eye lubricated. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AR-15512 ophthalmic solution (also called TRYPTYR or Acoltremon)
- What this could lead to
- If successful, this could lead to a new eye drop that helps restore the eye's natural moisture layer, offering better relief for dry eye disease.
- What could go wrong
- This is a small, completed Phase 3b study focused on a specific cell count, not symptoms. The treatment may not improve how patients feel, and results may not apply to all dry eye patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
80 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Mar 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Have a previous history of DED, clinician diagnosed or patient reported, within the previous 6 months prior to the Screening visit. * Have used artificial tears for DED symptoms within 2 months prior to the Screening visit. * Corrected visual acuity equal to or better than logarithm Minimum angle of reflection (logMar) +0.7 (Snellen equivalent equal to or better than 20/100), as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at both the Screening and Baseline visits. * Good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history. * Other protocol specified inclusion criteria may apply. Key Exclusion Criteria: * History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety. * Current evidence of other significant ophthalmic disease requiring topical medication (e.g., glaucoma, ocular hypertension), or other ophthalmic disease which the investigator believes may interfere with study findings or interpretation. * History of ocular surgery within 1 year prior to the Screening visit; history of corneal transplant in one or both eyes. * Use of contact lenses in either eye within 7 days prior to the Screening visit or planned use during the study. * Regular use, as assessed by the investigator, of lid hygiene or heat masks within 14 days prior to the Screening visit or any planned use during the study. * Use of lid heating therapy or Meibomian gland probing/therapeutic expression within 1 year prior to the Screening visit or anticipated during the study. * Other protocol-specified exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dry eye disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Butchertown Clinical Trials
Louisville, Kentucky, 40206, United States
-
CORE, Inc.
Shelby, North Carolina, 28150, United States
-
Oculus Research
Garner, North Carolina, 27529, United States
-
Wilmington Eye
Leland, North Carolina, 28451, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eyedrop heal the cornea in dry eye disease?
- Can a daily eye drop safely treat dry eye? phase 3 trial puts tivanisiran to the test
- Can tiny fat bubbles in eye drops soothe dry eyes?
- Can a new eye drop fully clear dry eye redness?
- Could a common dry eye drop shield the Cornea's inner layer?
- Dry eye gel may sharpen cataract surgery results